Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Formulation buffers · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Platform II, PASS, ARG 100 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Formulation buffers | OTHER | Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine |
Inclusion Criteria: * Healthy male or female subjects(no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory. * Body mass index of 17.5 to 30.5 kg/m2; and a to...
Formulation buffers is an investigational drug being studied in healthy subjects. It is being evaluated for tolerability when administered subcutaneously. The drug is currently in Phase 1 clinical development.
Formulation buffers is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY.
Formulation buffers is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study has been completed.
Formulation buffers has one completed Phase 1 clinical trial, identified as NCT01401764. This study compared the tolerability of three excipient formulations administered subcutaneously to healthy subjects in Belgium.
Yes, Formulation buffers is being studied in healthy volunteers. The completed Phase 1 trial enrolled 30 healthy subjects, with an age range starting at 18 years, and included both males and females.